Trospium chloride

Generic Medicine Info
Indications and Dosage
Overactive bladder
Adult: For the symptomatic treatment of urge urinary incontinence, urinary frequency and urgency: As conventional tab: 20 mg bid. As extended-release cap: 60 mg once daily in the morning. Reassess the need for continued therapy at regular intervals of 3-6 months.
Elderly: ≥75 years As conventional tab: 20 mg once daily based on patient tolerability.
Renal Impairment
CrCl (mL/min) Dosage
<30 As conventional tab: 20 mg once daily or 20 mg on alternate days. As extended-release cap: Not recommended.
Hepatic Impairment
Severe: Contraindicated.
Should be taken on an empty stomach. Take 1 hr before meals or on an empty stomach.
Existing or predisposition to urinary retention, gastric retention, severe gastrointestinal conditions (e.g. toxic megacolon), uncontrolled angle-closure glaucoma, myasthenia gravis, tachyarrhythmia. Severe hepatic impairment.
Special Precautions
Patient with bladder outflow obstruction, gastrointestinal obstructive disorders (e.g. pyloric stenosis), intestinal atony, ulcerative colitis, autonomic neuropathy, controlled/treated angle-closure glaucoma, hiatus hernia associated with reflux oesophagitis, conditions wherein fast heart rates are undesirable (e.g. CHF, coronary artery disease, hyperthyroidism); Alzheimer's disease. Extended-release cap: Not recommended for use in severe renal impairment. Renal and mild to moderate hepatic impairment. Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Decreased gastrointestinal motility; increased risk of urinary or gastric retention; CNS effects (e.g. drowsiness, dizziness, blurred vision, confusion, hallucinations).
Cardiac disorders: Tachycardia.
Eye disorders: Dry eyes.
Gastrointestinal disorders: Constipation, dyspepsia, dry mouth, nausea, abdominal pain, abdominal distention, flatulence, dysgeusia.
General disorders and administration site conditions: Fatigue.
Musculoskeletal and connective tissue disorders: Back pain.
Nervous system disorders: Headache.
Renal and urinary disorders: UTI.
Respiratory, thoracic and mediastinal disorders: Nasal dryness.
Skin and subcutaneous tissue disorders: Dry skin.
Potentially Fatal: Angioedema of face, lips, tongue or larynx.
Patient Counseling Information
This drug may cause dizziness, drowsiness, confusion, hallucinations, and/or blurred vision; if affected, do not drive or operate machinery.
Monitoring Parameters
Check the voiding patterns at baseline and periodically during treatment. Monitor renal function, postvoid residual (PVR) urine volume and UTI prior to therapy initiation; anticholinergic effects (e.g. dry mouth, constipation, dizziness).
Symptoms: Dry mouth, tachycardia, and micturition disorders. Management: Supportive and symptomatic treatment. Perform gastric lavage and administer activated charcoal. May administer local pilocarpine in patients with glaucoma. Catheterisation may be considered in patients with urinary retention. In severe cases, a parasympathomimetic agent (e.g. neostigmine) may be given. Administer β-blockers (e.g. 1 mg IV propranolol) and monitor ECG and blood pressure in case of insufficient response, pronounced circulatory instability and/or tachycardia.
Drug Interactions
Other agents that are eliminated by active tubular secretion (e.g. procainamide, pancuronium, vancomycin, morphine, tenofovir) may increase the serum concentration of trospium chloride and/or the coadministered drug. May decrease the exposure and peak serum levels with metformin immediate-release tab. May potentiate the effects of agents with anticholinergic action (e.g. amantadine, TCAs). May enhance the tachycardic effect of β-sympathomimetics. May decrease the efficacy of prokinetic agents (e.g. metoclopramide).
Food Interaction
Reduced absorption and bioavailability when taken with food, particularly high-fat meals. May cause additive sedative effects (e.g. drowsiness) with alcohol.
Mechanism of Action: Trospium chloride is a quaternary ammonium antimuscarinic agent which antagonises the effects of acetylcholine at muscarinic receptors located in the cholinergically innervated organs. It also reduces the contractile tone of smooth muscles in the urinary bladder.
Absorption: Incompletely absorbed from the gastrointestinal tract. Reduced absorption and bioavailability with food, particularly high-fat meals. Bioavailability: Conventional tab: Approx 10% (range: 4-16%). Time to peak plasma concentration: 4-6 hours.
Distribution: Volume of distribution: 395->600 L. Plasma protein binding: 48-85%.
Metabolism: Hypothesised to be metabolised via ester hydrolysis with subsequent conjugation of benzylic acid to form azoniaspironortropanol with glucuronic acid.
Excretion: Mainly via faeces (85%); urine (approx 6%; approx 60% as unchanged drug and approx 10% as the spiroalcohol metabolite). Elimination half-life: 10-20 hours (conventional tab); approx 35 hours (extended-release cap). Primarily eliminated via active tubular secretion.
Chemical Structure

Chemical Structure Image
Trospium chloride

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5284631, Trospium chloride. Accessed Jan. 26, 2021.

Store between 15-30°C.
MIMS Class
Drugs for Bladder & Prostate Disorders / Other Drugs Acting on the Genito-Urinary System
ATC Classification
G04BD09 - trospium ; Belongs to the class of urinary antispasmodics.
Anon. Trospium. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 08/01/2021.

Anon. Trospium. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 08/01/2021.

Buckingham R (ed). Trospium Chloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 08/01/2021.

Joint Formulary Committee. Trospium Chloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 19/01/2021.

Regurin 20 mg Coated Tablets (Mylan Products Ltd.). MHRA. Accessed 08/01/2021.

Regurin XL 60 mg Prolonged-Release Hard Capsule (Mylan Products Ltd.). MHRA. Accessed 19/01/2021.

Spasmolyt Tablet (Mylan Healthcare Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 08/01/2021.

Trospium Chloride Capsule, Extended Release (Bluepoint Laboratories). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/01/2021.

Trospium Chloride Tablet, Film Coated (Cipla USA Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/01/2021.

Uraplex 20 mg Coated Tablets (Mylan Products Ltd.). MHRA. Accessed 08/01/2021.

Disclaimer: This information is independently developed by MIMS based on Trospium chloride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in